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The activity of the NMDA receptor (NMDAR), which is a glutamate-gated ion channel, is a key
factor influencing the neuronal damage following cerebral ischemia. NMDAR is composed of two
essential GluN1 subunits and two regionally localized GluN2 or GluN3 subunits. GluN1, GluN2A,
and GluN2B are the primary NMDAR subunits in the adult forebrain. Thus, the three major
NMDAR subtypes in the adult forebrain are the GluN1/2A receptor, the GluN1/2B receptor, and the
GluN1/2A/2B receptor. The functional properties of these NMDARs depend mainly on the GluN2
subunits, and many studies primarily classify NMDARs as GluN2A- and GluN2B-containing
NMDARs. However, given the influence of the triheteromeric GluN1/2A/2B receptor, this
misclassification might lead to a misunderstanding of the physiological and pathological roles of
GluN2, especially the GluN2A subunit. Understanding the role of the GluN1/2A/2B receptor in
cerebral ischemia may be critical for identifying the specific role of the GluN2A subunit, which
may mediate pro-survival effects following cerebral ischemia.
EXPRESSION OF THE GLUN1/2A/2B RECEPTOR IN THE RAT
ADULT FOREBRAIN
The results of a sequential immunoprecipitation study revealed that 60–70% of GluN2A and
70–85% of GluN2B subunits in the CA1/CA2 of rat hippocampus are diheteromeric (Al-Hallaq
et al., 2007). However, other studies suggest that the majority of NMDARs in the adult forebrain
are triheteromeric GluN1/2A/2B receptors. Using quantitative immunoprecipitation analysis, Luo
et al. found that the dominant NMDAR complex in the adult rat cortex contains three subunits,
i.e., GluN1, GluN2A, and GluN2B (Luo et al., 1997). Subsequently, in a comparison of the
NMDAR-mediated excitatory postsynaptic current decay time of wild-type mice with those of
Grin2A−/− and Grin2B1Fb mice, Rauner et al. demonstrated that the triheteromeric GluN1/2A/2B
receptor is prominently expressed in the CA1 synapses of adult wild-type mice (Rauner and Köhr,
2011). Tovar et al. reported that at least two-thirds of NMDARs in hippocampal synapses are
triheteromeric receptors, based on an analysis of the NMDAR deactivation kinetics in response
to the competitive GluN2A antagonist NVP-AAM077 (Tovar et al., 2013). Delaney et al. found that
the triheteromeric GluN1/2A/2B receptor is the primary synaptic NMDAR in principal neurons
of the basolateral amygdala (Delaney et al., 2013). Through examining the relationship between
spatial cognition and protein–protein interactions of GluN2B-containing NMDARs, Zamzow et al.
speculated that there were more GluN1/2A/2B receptors in older mice than in young adults
(Zamzow et al., 2013). Together, these data indicate that the triheteromeric GluN1/2A/2B receptor
is the most common NMDAR in the adult forebrain.
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PHARMACOLOGICAL PROPERTIES OF
THE GLUN1/2A/2B RECEPTOR
Recently, two independent research groups specifically expressed
the triheteromeric GluN1/2A/2B receptor on the cell surface
using the trafficking control system of GABAB receptors,
while the cell surface expression of diheteromeric NMDARs
(GluN1/2A and GluN1/2B receptors) was inhibited (Hansen
et al., 2014; Stroebel et al., 2014). Several lines of evidence show
that compared to the selective GluN2B antagonists, selective
GluN2A antagonists profoundly inhibit the GluN1/2A/2B
receptors. The IC50 of TCN-201, a selective GluN2A antagonist,
increased from 370 ± 30 nM for the wild-type GluN1/2A
receptor to 1350 ± 130 nM for the GluN1/2A/2B receptors,
and maximal inhibition was reduced from 91 ± 1 to 72 ±
4% (Hansen et al., 2014). Compared to that of the wild-
type GluN1/2B receptor, the IC50 of ifenprodil, a selective
GluN2B antagonist, increased 6.3-fold for the triheteromeric
GluN1/2A/2B receptor, and maximal inhibition was reduced to
32 ± 1% (Hansen et al., 2014). Consistent with these results,
Cheriyan et al. found that the GluN2A-selective inhibitors
TCN-201 and NVP showed a similar inhibitory effect on
diheteromeric and triheteromeric GluN2A-containing receptors,
while the GluN2B-selective inhibitors ifenprodil, con-G, and
con-RlB only inhibited triheteromeric GluN1/2A/2B receptor
currents by 19.14, 5.5, and 14.3%, respectively (Cheriyan
et al., 2016). Interestingly, Stroebel et al. observed a biphasic
curve when evaluating the ifenprodil-induced inhibition of the
GluN1/2A/2B receptor, and the majority of this inhibition,
which increased 77%, was due to the low-affinity component
(Stroebel et al., 2014). Thus, the GluN1/2A/2B receptor
is sensitive to selective GluN2A antagonists. As a result,
the effects of GluN2A antagonists may be due to the
blockage of both GluN1/2A and GluN1/2A/2B receptors, which
FIGURE 1 | Putative mechanism of selective GluN2A antagonism after cerebral ischemia. The conditions of this putative mechanism include the GluN2A
subunit mainly mediating a pro-survival effect after cerebral ischemia and the GluN1/2A/2B receptor acting as a pro-death factor with a more dominant role than the
GluN1/2A receptor.
may confound investigations on the role of the GluN2A
subunit.
THE ROLE OF THE GLUN1/2A/2B
RECEPTOR IN CEREBRAL ISCHEMIA
GluN2B promotes cell death following cerebral ischemia,
activating many pro-death signaling molecules, such as neuronal
nitric oxide synthase (nNOS) and death-associated protein
kinase 1 (DAPK1) (Lai et al., 2014). However, the role
of GluN2A in cerebral ischemia remains controversial (Sun
et al., 2016). Notably, previous studies of cerebral ischemia
have ignored the influence of the triheteromeric GluN1/2A/2B
receptor despite the fact that this receptor accounts for a
large proportion of the NMDARs in the adult forebrain.
Considering the strong inhibitory effect of GluN2A-specific
antagonists on the triheteromeric GluN1/2A/2B receptor, the
role of the GluN2A subunit in cerebral ischemia may be worth
further consideration. For example, although the GluN1/2A
receptor might mediate pro-survival signaling during cerebral
ischemia, the GluN1/2A/2B receptor could either promote cell
survival or promote cell death. If the GluN1/2A/2B receptor
promotes cell death and plays a more dominant role than
the GluN1/2A receptor, the total effect of GluN2A antagonists
on a cell expressing both the GluN1/2A/2B receptor and the
GluN1/2A receptor might be pro-survival (Figure 1). In this
circumstance, the pro-survival effect of GluN2A antagonists
would incorrectly suggest that the GluN2A subunit promotes cell
death during cerebral ischemia, leading to a misunderstanding of
the role of GluN2A in cerebral ischemia. Given this possibility,
further studies should investigate the effect of the triheteromeric
GluN1/2A/2B receptor on cerebral ischemia. Papouin et al. found
that the preferential GluN2A antagonist zinc, but not the selective
GluN2B antagonist Ro25-6981, had a significant neuroprotective
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effect on the neuronal death induced by NMDA exposure in
acute hippocampal slices (Papouin et al., 2012). Given the high
expression level of the GluN1/2A/2B receptor in the hippocampal
neurons (Rauner and Köhr, 2011) and the significant inhibitory
effect of zinc on the GluN1/2A/2B receptor (Hansen et al., 2014),
the triheteromeric NMDARs, but not the GluN1/2A receptor,
located at synaptic sites may mediate the neurotoxic effect
of NMDA on CA1 pyramidal neurons. Such a mechanism is
consistent with our hypothesis.
PERSPECTIVES
Investigating the GluN1/2A/2B receptor may lead to a re-
evaluation of the treatment strategies for several neurological
diseases related to excitotoxicity, such as stroke, Alzheimer’s
disease (AD), and Huntington’s disease (HD). Previous studies
suggest that for AD or HD, similar to stroke, overactivation
of the NMDAR results in neuronal damage (Dau et al.,
2014; Guivernau et al., 2016). However, it is still unclear
whether the GluN1/2A or GluN1/2A/2B receptor mediates
amyloid-beta- or mutant huntingtin-induced neurotoxicity.
The GluN1/2A receptor and the GluN1/2A/2B receptor may
play different roles in these diseases. Further studies should
investigate whether blockage of the GluN1/2A/2B receptor
protects against stroke, AD, or HD. If so, the GluN1/2B
and GluN1/2A/2B receptor antagonists might have a better
application prospect than existing GluN2B antagonists. Research
in this area may also contribute to investigating whether the
failure of GluN2B antagonists in clinical trials was due to the
poor selectivity of GluN2B antagonists on the GluN1/2A/2B
receptor.
NMDAR hypofunction may play a critical role in the
pathophysiological process of schizophrenia, and NMDAR
agonist treatment may improve patient symptoms (Kantrowitz
et al., 2016). In an effort to avoid excitotoxicity, we should clarify
whether a selective GluN1/2A receptor agonist is more effective
than a non-selective GluN1/2A and GluN1/2A/2B receptor
agonist.
Some evidence suggests that overactivation of synaptic
NMDARs is responsible for neurodegeneration (Papouin et al.,
2012; Zhou et al., 2015). However, this idea is inconsistent
with the current prevailing theory that describes extrasynaptic
NMDARs as a major pro-death factor (Hardingham and Bading,
2010). Notably, previous studies have not taken into account the
effect of the GluN1/2A/2B receptor. Understanding the role of
the GluN1/2A/2B receptor may be the key to explaining these
conflicting results.
Future studies should clarify the subcellular distribution,
signaling, and physiological and pathological functions of the
GluN1/2A/2B receptor. Such research will lead to insight on the
physiological and pathological functions of the three NMDAR
subtypes found in the adult forebrain, and the specific roles of
the GluN2A and GluN2B subunits. Current NMDAR antagonists
show varying degrees of specificity; thus, selective antagonists
of the GluN1/2A, GluN1/2B, and GluN1/2A/2B receptor are
urgently needed. GluN2A or GluN2B antisense oligonucleotides
and peptide mimetics may also be useful in this regard.
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